Wednesday, July 8, 2026

Patent intelligence · US

US 12173274

Enhanced immune effector cells and use thereof

granted A61KA61K2039/505A61K2039/507A61K35/545
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 53
Patent details — US 12173274
Jurisdiction
US
Status
granted
Grant date
Dec 24, 2024
Expiration
Dec 19, 2044
Claims
22
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K35/545
View on Google Patents ↗

Quick answer

US 12173274 (Enhanced immune effector cells and use thereof) is held by Fate Therapeutics, Inc.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
22
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K35/545, A61K38/00, A61K39/3955

More from Fate Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12410403

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Sep 4, 2045

    granted
  3. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  4. US 12385012

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  5. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Apr 17, 2045

    granted
  6. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Expires Apr 10, 2045

    granted
  7. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Expires Mar 27, 2045

    granted
  8. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Expires Mar 6, 2045

    granted

Frequently asked questions

What is US patent 12173274?

US 12173274 (Enhanced immune effector cells and use thereof) is held by Fate Therapeutics, Inc.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12173274?

Fate Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.

When does US 12173274 expire?

Our index shows an expiration date of Dec 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.